INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit

NACompletedINTERVENTIONAL
Enrollment

447

Participants

Timeline

Start Date

June 2, 2021

Primary Completion Date

December 17, 2024

Study Completion Date

December 17, 2024

Conditions
HIV InfectionsDrug UseOpioid UseOpioid-use Disorder
Interventions
DRUG

Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD)

MOUD for OUD

DIAGNOSTIC_TEST

HIV testing

HIV testing

DRUG

HIV treatment for participants living with HIV not already in care

HIV treatment for participants living with HIV not already in care

DRUG

PrEP for participants without HIV

PrEP for participants without HIV

DIAGNOSTIC_TEST

Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV)

Testing and referral for vaccination or treatment for HAV and HBV

DIAGNOSTIC_TEST

Testing and referral for treatment for hepatitis C virus (HCV)

Testing and referral for treatment for HCV

DIAGNOSTIC_TEST

Sexually transmitted infection (STI) testing and treatment

STI testing and treatment

OTHER

Primary care

Primary care

BEHAVIORAL

Harm reduction services

Harm reduction services

BEHAVIORAL

Peer navigation

Peer navigation

DIAGNOSTIC_TEST

COVID-19 testing and referral for further evaluation, care and/or treatment

COVID-19 testing and referral for further evaluation, care and/or treatment

Trial Locations (5)

10451

Bronx Prevention Center CRS, The Bronx

19104

Penn Prevention CRS, Philadelphia

20007

George Washington University CRS, Washington D.C.

77030

Houston AIDS Research Team CRS, Houston

90095

UCLA Vine Street Clinic, Los Angeles

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

HIV Prevention Trials Network

NETWORK